TRANSECT 03 · ADVERSE-EVENT LOG
TB-500 Side Effects Reported in the Literature
What the preclinical adverse-event record contains, what the human safety record does not, and the regulatory status as documented by WADA and the racing commissions.
Reported TB-500 side effects
TB-500 side effects in the published record divide into three categories. First, animal-study and anecdotal-use reports of injection-site reactions, lethargy, and transient flu-like symptoms — none of which have been characterized in controlled human trials of the LKKTETQ fragment. Second, the theoretical concern that Tβ4's pro-angiogenic and pro-migratory mechanism could affect existing undiagnosed malignancy — a concern grounded in the Cha 2003 finding that Tβ4 overexpression in solid-tumor models increased tumor cell migration, blood-vessel density, and metastatic lung nodules in mice [11]. Third, the analytical and regulatory consequences: detection by LC-MS in equine urine and plasma at sub-nanogram-per-milliliter sensitivity [16][19], with WADA prohibition since 2012.
Human side-effect data for the TB-500 heptapeptide fragment specifically are limited. The human safety record for full-length Tβ4 — derived from the RGN-352 IV Phase 1 in healthy volunteers and the RGN-259 ophthalmic Phase 2 and Phase 3 trials [12][13][14] — describes a generally acceptable safety profile in short-duration studies of the parent peptide. That record does not extend to long-duration use, to the fragment, or to general populations outside the trial inclusion criteria.
Is TB-500 safe?
Long-term human safety for TB-500 (the LKKTETQ fragment) has not been established. No completed Phase 3 trial of the fragment exists. Human safety data for full-length Tβ4 come from short-duration Phase 1 IV dosing [14] and from topical ophthalmic Phase 2 and Phase 3 trials [12][13][15] — neither dataset extrapolates cleanly to long-term systemic exposure to the fragment. The compound is banned by WADA at all times and by the Association of Racing Commissioners International for performance use [16].
Are there any negative side effects of TB-500?
Animal-study and anecdotal reports include injection-site reactions, lethargy, and theoretical concerns about angiogenesis-related effects on existing tumors derived from the Cha 2003 preclinical work [11]. Human side-effect data for the LKKTETQ fragment are limited. The full-length Tβ4 human safety record from Phase 1 IV [14] and Phase 2/3 ophthalmic trials [12][13] does not establish long-term systemic safety for the fragment.
The angiogenesis-and-tumor signal — Cha 2003 in context
The Cha 2003 paper in the Journal of the National Cancer Institute reported that Tβ4 overexpression in solid-tumor models increased tumor cell migration, blood-vessel density, and metastatic lung nodules in mice — using adenoviral overexpression rather than exogenous peptide administration [11]. This is the basis for theoretical oncologic-safety concerns about exogenous Tβ4 or TB-500 in subjects with undiagnosed malignancy. The signal is preclinical, mechanistically plausible given the angiogenesis pathway, and unaddressed by any completed human safety trial of the fragment.
TB-500 and anti-doping status
TB-500 (and thymosin beta-4 generally) is prohibited at all times under WADA's Section S2 — peptide hormones, growth factors, related substances and mimetics — as well as by the Association of Racing Commissioners International [16]. The WADA listing has been in effect since 1 January 2012. The Association of Racing Commissioners International treats TB-500 as an ARCI Class 1 substance in horse racing. Analytical detection is well established: Ho 2012 validated an LC-MS method for TB-500 in equine urine and plasma [16], and Esposito 2012 confirmed the structural identity of commercial TB-500 and validated detection sensitivity to 0.02 ng/mL in plasma and 0.01 ng/mL in urine [19]. Exogenous TB-500 is distinguishable from endogenous Tβ4 by current anti-doping methods.
Is TB-500 banned by WADA?
Yes. TB-500 (and thymosin beta-4) is prohibited at all times under WADA's S2 class — peptide hormones, growth factors, related substances and mimetics — as well as by the Association of Racing Commissioners International. The listing has been in effect since 1 January 2012. Analytical detection by LC-MS is in active anti-doping use [16][19].
What the human safety record does not contain
There is no completed Phase 3 human trial of the LKKTETQ fragment. There is no published validated human pharmacokinetic profile for the fragment. There is no long-duration safety dataset for systemic TB-500 in any population. The Phase 2 RGN-352 trial in acute myocardial infarction was placed on FDA clinical hold in 2011 due to contract-manufacturer cGMP non-compliance and was not completed; that trial would have generated the most directly relevant cardiac-safety data. Most clinical-trial efficacy data come from the full-length 43-residue Tβ4, not the heptapeptide fragment actually sold as TB-500 — extrapolation from full-length-peptide trials to fragment safety in humans is not validated.